Reports

225 Results (Page 1 of 9)

Australia Markets Research Reports

Pharmaceuticals

Australia Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Analysis

Australia's Chronic Obstructive Pulmonary Disease (COPD) therapeutics market was valued at $219 Mn in 2022 and is estimated to expand at a CAGR of 8.6% from 2022 to 2030 and will reach $424 Mn in 2030. One of the main reasons propelling the growth of this market is Technological advancements, and increasing awareness. The market is segmented by Drug class and By distribution channel. Some key players in this market are F. Hoffmann-La Roche, Mylan N.V, Merck & Co, Vectura Group, Astellas Pharma, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Novartis, Pfizer, Teva Australia Limited and others.

PUBLISHED: Mar, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2024 | PRICE: $3999

Rare Diseases

Australia X-Linked Myotubular Myopathy (XLMTM) Drugs Market Analysis

Australia X-Linked Myotubular Myopathy (XLMTM) Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for X-Linked Myotubular Myopathy (XLMTM) Drugs is growing rapidly as a result of unmet medical need for therapies of X-Linked Myotubular Myopathy (XLMTM) disease, advancements in gene therapy, Growing Awareness and Patient Advocacy about the disease, Increased Research and Collaboration between research organizations and pharmaceutical companies, supportive regulatory environments, Technological Advancements in gene sequencing and biomarker identification. Novartis Gene Therapies, Avrobio, Axovant Gene Therapies, Sarepta Therapeutics, Amicus Therapeutics, Sanofi Genzyme, Pfizer, Audentes Therapeutics are the key market players operating in global X-Linked Myotubular Myopathy (XLMTM) Drugs market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2024 | PRICE: $3999

Rare Diseases

Australia Oculopharyngeal Muscular Dystrophy (OPMD) Market Analysis

Australia Oculopharyngeal Muscular Dystrophy (OPMD) market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Oculopharyngeal Muscular Dystrophy (OPMD)is growing due to increase spending in research and development activities by pharmaceutical companies, incentives provided by regulatory authorities like orphan drug designations and accelerated approval pathways, patient support and advocacy programmes which help to increase awareness about disease and provide support to patients. Bristol-Myers Squibb, BioMarin, Sarepta Therapeutics, Benitec Biopharma Inc., Bioblast Pharma, PTC Therapeutics, NS Pharma, Nobelpharma Co., Ltd ,Santhera Pharmaceuticals, Pfizer Inc. ,Marathon Pharmaceuticals, Fibrogen, GSK are the key global market players.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2024 | PRICE: $3999

Rare Diseases

Australia Neuromyelitis Optica Spectrum Disorder (NMOSD) Drugs Market Analysis

Australia Neuromyelitis Optica Spectrum Disorder (NMOSD) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Increasing awareness and diagnosis, Increasing funding for medical infrastructure and high rate of multiple sclerosis prevalence (MS), unmet medical needs, advancements in drug development, Regulatory Approvals of drugs like eculizumab, inebilizumab and satralizumab , rising healthcare expenditure and growing collaborations in research and development of drugs are the major drivers for Neuromyelitis Optica Spectrum Disorder (NMOSD) drugs Market. Major global players in Neuromyelitis Optica Spectrum Disorder (NMOSD) drugs Market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Zydus Cadila (India), Boehringer Ingelheim International GmbH. (Germany), Apotex Inc. (Canada), AstraZeneca (U.K.), Horizon Therapeutics PLC (Ireland), Johnson & Johnson Private Limited (U.S.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), LEO Pharma A/S (Denmark).

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2024 | PRICE: $3999

Rare Diseases

Australia Morquio Syndrome (MPS-IV) Drugs Market Analysis

Australia Morquio Syndrome (MPS-IV) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. As genetic illnesses like Morquio Syndrome (MPS-IV) has become more common, there is an increasing demand for specialised drugs to treat them. Unmet clinical demands and improved treatment outcomes, Orphan Drug Designation and Incentives, Patient Advocacy and Support programmes. Major global players in Morquio Syndrome (MPS-IV) Drugs Market are BioMarin, Genzyme Corporation, Shire, JCR Pharmaceuticals Co., Ltd., Sanofi, Sangamo Drugs, ArmaGen and GREEN CROSS CORP, Concert Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., and other players.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2024 | PRICE: $3999

Rare Diseases

Australia Fragile-X Syndrome Therapeutics Market Analysis

Australia Fragile-X Syndrome Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The most typical cause of inherited learning disabilities is fragile X syndrome (FXS), an X-linked genetic disorder. The global market is driven by the higher prevalence of males than females, the transmission of the disease from one generation to the next, and the rise in patients suffering from this and other genetic disorders. Aelis Farma Sas, Alcobra Ltd, Amo Pharma Limited, Confluence Pharmaceuticals Llc, F. Hoffmann-la Roche Ltd., Marinus Pharmaceuticals, Mi.to. Technology S.r.l., Neuren Pharmaceuticals Limited, Ovid Therapeutics Inc., Sage Therapeutics, Acadia Pharmaceuticals, Advanz Pharma Corp, Boehringer Ingelheim, GlaxoSmithKline, H. Lundbeck, Janssen, Novartis, Ots.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2024 | PRICE: $3999

Rare Diseases

Australia Adrenoleukodystrophy (ALD) Drugs Market Analysis

Australia Adrenoleukodystrophy (ALD) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Drivers of acromegaly market are increasing cases of the disorder which in turn increased awareness and government focus motivated financial support to R&D. Poxel SA, Bluebird Bio Inc.,Viking Technologies, Minoryx Therapeutics sl., Apteeus SAS, Ashvattha Therapeutics LLC, NeuroVia Company, Autobahn Therapeutics Inc., Aldagen Inc., Celularity Inc., Imstem Biotechnology Inc., MedDay SA, and Orpheris Inc. are major competitors in the Global Adrenoleukodystrophy (ALD) drugs Market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2024 | PRICE: $3999

Rare Diseases

Australia Myeloproliferative Disorders (MPD) Therapeutics Market Analysis

Australia Myeloproliferative Disorders (MPD) therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The market for drugs to treat myeloproliferative disorders is expected to expand as a result of the rising prevalence of the different myeloproliferative disorders, the existence of promising pipeline products, regular product approvals, and rising R&D expenditures on the creation of new drugs for the MPD Treatment market. Major global players in this market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Mylan N.V, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd, Bristol Myers Squibb Company, GSK Plc, Bayer AG, Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim International Gmbh, Sanofi.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2024 | PRICE: $3999

Rare Diseases

Australia Spinal Muscular Atrophy (SMA) Therapeutics Market Analysis

Australia Spinal Muscular Atrophy (SMA) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market is expanding as a result of rising SMA instances, technological advancements, government encouragement, rising consumer awareness, and increased R&D activities. Major global players in Spinal Muscular Atrophy (SMA) Therapeutics Market are Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland), Boehringer Ingelheim International GmbH. (Germany), GSK plc (U.K.), Novartis AG (Switzerland), Biogen (U.S.), Pfizer Inc.(U.S.), Ionis Pharmaceuticals, Inc. (U.S.), Regeneron Pharmaceuticals Inc (U.S.)., Abbott (U.S.), AbbVie Inc. (U.S.), Novo Nordisk A/S (Denmark), Takeda Pharmaceutical Company Limited (Japan), AstraZeneca (U.K.), Leadiant Biosciences, Inc.(Italy), Catalyst Pharmaceuticals, Inc.(U.S.), PTC Therapeutics (U.S.)

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2024 | PRICE: $3999

Rare Diseases

Australia Cystic Fibrosis (CF) Therapeutics Market Analysis

Australia Cystic Fibrosis (CF) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Cystic fibrosis (abbreviated CF) is a genetic disorder that causes mucus to build up in certain organs of the body, particularly the lungs and pancreas, resulting in breathing problems, respiratory infections and faulty digestion. The increasing prevalence of Cystic Fibrosis (CF) coupled with the rising treatment rate is one of the key factors anticipated to propel the demand for cystic fibrosis therapeutics over the forecast period. The key players are consistently involved in the development of new or combination of products to treat cystic fibrosis. Investment in the R&D is one of the strategic measures to beat the competition. The key players in this market are AbbVie Inc.; F. Hoffmann-La Roche Ltd; Gilead; Novartis AG; Vertex Pharmaceuticals Inc.; AIT (Advanced Inhalation Therapies); Alaxia; Teva Pharmaceutical Industries Ltd; Merck & Co. Inc.; Alcresta Therapeutics Inc.; Allergan; and AstraZeneca.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jun, 2024 | PRICE: $3999

Clinical Trials

Australia Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market Analysis

This report presents a strategic analysis of the Australia Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Australia Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market, offering unmatched value, accuracy and expert insights.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Jun, 2024 | PRICE: $3999

Clinical Trials

Australia Clinical Trials Support Service Market Analysis

This report presents a strategic analysis of the Australia Clinical Trials Support Service Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Australia Clinical Trials Support Service Market, offering unmatched value, accuracy and expert insights.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Jun, 2024 | PRICE: $3999

Clinical Trials

Australia COVID-19 Clinical Trials Market Analysis

This report presents a strategic analysis of the Australia COVID-19 Clinical Trials Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Australia COVID-19 Clinical Trials Market, offering unmatched value, accuracy and expert insights.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Jun, 2024 | PRICE: $3999

Pharmaceuticals

Australia Advanced Therapy Medicinal Products (ATMPs) Market Analysis

This report presents a strategic analysis of the Australia Advanced Therapy Medicinal Products (ATMPs) Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Australia Advanced Therapy Medicinal Products (ATMPs) Market, offering unmatched value, accuracy and expert insights.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Jun, 2024 | PRICE: $3999

Rare Diseases

Australia Multiple Myeloma Therapeutics Market Analysis

Australia multiple myeloma therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The increased prevalence of the illness, new technologies, and improved healthcare systems are a few of the elements boosting the revenue of the worldwide multiple myeloma market. Major global players in this market are Teva Pharmaceutical Industries Ltd. Takeda Pharmaceutical Company Limited Genentech Inc. (F. Hoffmann-La Roche Ltd) Novartis AG Celgene Corporation (Bristol Myers Squibb Company) Janssen Pharmaceuticals Inc. (Johnson & Johnson) AbbVie Inc. Ono Pharmaceutical Co. Ltd. Sanofi S.A. Pfizer Inc. Merck & Co. Inc. Eli Lilly and Company Cipla Inc

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jun, 2024 | PRICE: $3999

Rare Diseases

Australia Multiple Myeloma Therapeutics Market Analysis

Australia's multiple myeloma therapeutics market was valued at $100 Mn in 2022 and is estimated to expand at a CAGR of 6% from 2022 to 2030 and will reach $160 Mn in 2030. One of the main reasons propelling the growth of this Market is Increasing healthcare expenditure, Increasing geriatric population. The Market is segmented by type, drug, and distribution channel. Some key players in this Market are CSL, Telix Pharmaceuticals, Mesoblast, Kazia Therapeutics, Immutep, Patrys, Actinogen Medical, Noxopharm, Prima BioMed, Polynovo, and others.

PUBLISHED: Mar, 2023 | FORMAT: PPT | LAST UPDATED: Jun, 2024 | PRICE: $3999

Digital Health

Australia Healthcare Financial Analytics Market Analysis

Australia's healthcare financial analytics market size was valued at $xx Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 8.3% from 2022 to 2030 and will reach $xx Mn in 2030. The market is segmented by type, component, and deployment. Australia’s Healthcare Financial Analytics market will grow as the rising cost of healthcare in Australia is driving the need for financial analytics solutions that can help healthcare organizations manage and optimize their spending. The key market players are ClinTrial Refer, Advantech, HotDoc, Health Metrics, IQVIA, and others.

PUBLISHED: Mar, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Digital Health

Australia Electronic Health Records Market Analysis

Australia's Electronic Health Record market size was valued at $339 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 5.5% from 2022-30 and will reach $521 Mn in 2030. Australia's EHR market growth will grow as EHRs give doctors access to more thorough patient data, empowering them to swiftly decide on the best course of treatment, enhance patient care, and reduce safety risks. The key market players are Medical Director, Zedmed, Genie Solutions, Allscripts, Cerner, Epic Systems, and others.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

OTC & Nutraceuticals

Australia Over The Counter (OTC) Drugs Market Analysis

Australia Over The Counter (OTC) Drugs Market is projected to grow from $2.043 Bn in 2022 to $3.954 Bn by 2030, registering a CAGR of 8.60% during the forecast period of 2022 - 2030. The introduction of new technologies, such as digital health platforms, can also drive the OTC drug market in Australia by making it easier for consumers to access and purchase these products. There are a number of key players in the over-the-counter (OTC) drug market in Australia like Johnson & Johnson, GlaxoSmithKline, and Procter & Gamble.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Pharmaceuticals

Australia Antibacterial (Antibiotics) Drugs Market Analysis

This report presents a strategic analysis of the Australia Antibacterial (Antibiotics) Drugs Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the Australian antibacterial (Antibiotics) Drugs Market, offering unmatched value, accuracy, and expert insights.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Australia Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Market Analysis

Australia Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Increasing funding for medical infrastructure and high rate of multiple sclerosis prevalence (MS) are the major drivers for Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Market. Major global players in Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Zydus Cadila (India), Boehringer Ingelheim International GmbH. (Germany), Apotex Inc. (Canada), AstraZeneca (U.K.), Horizon Therapeutics PLC (Ireland), Johnson & Johnson Private Limited (U.S.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), LEO Pharma A/S (Denmark).

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Pharmaceuticals

Australia Obesity Drugs Market Analysis

This report presents a strategic analysis of the Australia Obesity Drugs Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Australia Obesity Drugs Market, offering unmatched value, accuracy and expert insights.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Digital Health

Australia Blockchain Technology in Healthcare Market Analysis

This report presents a strategic analysis of the Australia Blockchain Technology in Healthcare Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Australia Blockchain Technology in Healthcare Market, offering unmatched value, accuracy and expert insights.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Pharmaceuticals

Australia Oncology Therapeutics Market Analysis

By 2030, it is anticipated that the Australia Oncology Therapeutics Market will reach a value of $4.6 Bn from $2.2 Bn in 2022, growing at a CAGR of 9.9% during 2022-2030. The Oncology Therapeutics Market in Australia is dominated by a few domestic pharmaceutical companies such as CSL Behring, Mesoblast, and Sirtex Medical. The Oncology Therapeutics Market in Australia is segmented into different types of cancer and different therapy type. The major risk factors associated with cancer are diet, alcohol, tobacco, air pollution, and physical inactivity. The demand for Australia Oncology Therapeutics is increasing on account of the rise in initiatives taken by the Government of the country.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Medical Devices

Australia Neurology Devices Market Analysis

Australia Neurology Device Market size is at around $151.44 Mn in 2022 and is projected to reach $308.46 Mn in 2030, exhibiting a CAGR of 9.3% during the forecast period. Australia is a major importer of neurology devices and suffers from a major burden of neurology diseases the market is well-captured by players like Medtronics, BHP Group, Rio Tinto, and Westpac. This report by Insights10 is segmented by product type like neurostimulation, interventional neurology, neurosurgery devices, and neuro-endoscopes, and by the end user.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

subscribe to our newsletter
up